Symphogen is a leader in the development of antibody mixtures to improve the treatment of cancer.
Symphogen’s technology is uniquely suited for targeting multiple molecules, which is key to dealing with complex diseases such as cancer.
The Danish company, based in Copenhagen, generates revenues from out-licensing drug candidates to large pharmaceutical companies. Its pipeline addresses large commercial markets (> $1 billion) in oncology.
Since Gilde invested in Symphogen, the company has expanded and advanced its product pipeline, and strengthened and broadened its technology platform. Its lead oncology product was out-licensed to Merck in 2012 following a positive phase-2 trial in late-stage cancer patients. Symphogen also initiated commercial agreements with Genentech.